A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists

被引:51
作者
Vauquelin, G [1 ]
Morsing, P
Fierens, FLP
De Backer, JP
Vanderheyden, PML
机构
[1] Free Univ Brussels, Dept Mol & Biochem Pharmacol, Rhode St Genese, Belgium
[2] AstraZeneca, Dept Cardiovasc Pharmacol, Molndal, Sweden
关键词
AT(1) antagonists; CHO cells; inositol phosphate; candesartan; irbesartan; EXP3174; losartan; surmountable; insurmountable;
D O I
10.1016/S0006-2952(00)00546-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interaction between non-peptide antagonists and the human angiotensin II type 1 (AT(1)) receptor in CHO-K1 cells was investigated by incubating the cells with antagonist, followed by a brief exposure to angiotensin II and measurement of the resulting inositol phosphate accumulation. The experimental data, expressed either as angiotensin II concentration-response curves or as antagonist concentration-inhibition curves, were in good agreement with computer-generated data according to a single-state model for the surmountable antagonist losartan and according to a two-step. two-state receptor model for the insurmountable antagonists candesartan, EXP3174. and irbesartan. Experimental and computer-generated data concerning the simultaneous exposure of the receptors to EXP3174 and losartan indicated that losartan produced a concentration-dependent restoration of the maximal response (angiotensin II concentration-response curves) as well as a rightward shift of the insurmountable portion of the EXP3174 inhibition curves, thus counteracting the higher-affinity EXP3174 binding. In conclusion. these findings provide further support for the concept that insurmountable and surmountable AT(1) antagonists are mutually competitive and that insurmountable antagonist-receptor complexes may adopt different states, (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:277 / 284
页数:8
相关论文
共 32 条
[1]   PHARMACOLOGY OF A POTENT LONG-ACTING IMIDAZOLE-5-ACRYLIC ACID ANGIOTENSIN AT(1) RECEPTOR ANTAGONIST [J].
AIYAR, N ;
BAKER, E ;
VICKERYCLARK, L ;
OHLSTEIN, EH ;
GELLAI, M ;
FREDRICKSON, TA ;
BROOKS, DP ;
WEINSTOCK, J ;
WEIDLEY, EF ;
EDWARDS, RM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 283 (1-3) :63-72
[2]  
Andersson Ove K., 1998, Blood Pressure, V7, P53
[3]   Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan [J].
Azizi, M ;
Chatellier, G ;
Guyene, TT ;
Ménard, J .
JOURNAL OF HYPERTENSION, 1999, 17 (04) :561-568
[4]  
CAZAUBON C, 1993, J PHARMACOL EXP THER, V265, P826
[5]   PHARMACOLOGY OF LR-B/081, A NEW HIGHLY POTENT, SELECTIVE AND ORALLY-ACTIVE, NONPEPTIDE ANGIOTENSIN-II AT(1) RECEPTOR ANTAGONIST [J].
CIRILLO, R ;
RENZETTI, AR ;
CUCCHI, P ;
GUELFI, M ;
SALIMBENI, A ;
CALIARI, S ;
CASTELLUCCI, A ;
EVANGELISTA, S ;
SUBISSI, A ;
GIACHETTI, A .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (06) :1117-1124
[6]   PHARMACOLOGICAL PROFILE OF VALSARTAN - A POTENT, ORALLY-ACTIVE, NONPEPTIDE ANTAGONIST OF THE ANGIOTENSIN-II AT1-RECEPTOR SUBTYPE [J].
CRISCIONE, L ;
DEGASPARO, M ;
BUHLMAYER, P ;
WHITEBREAD, S ;
RAMJOUE, HPR ;
WOOD, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (02) :761-771
[7]   THE SEROTONIN-S2 RECEPTOR - A RECEPTOR-TRANSDUCER COUPLING MODEL TO EXPLAIN INSURMOUNTABLE ANTAGONIST EFFECTS [J].
DECOURCELLES, DC ;
LEYSEN, JE ;
ROEVENS, P ;
VANBELLE, H .
DRUG DEVELOPMENT RESEARCH, 1986, 8 (1-4) :173-178
[8]   BMS-180560, AN INSURMOUNTABLE INHIBITOR OF ANGIOTENSIN II-STIMULATED RESPONSES - COMPARISON WITH LOSARTAN AND EXP3174 [J].
DICKINSON, KEJ ;
COHEN, RB ;
SKWISH, S ;
DELANEY, CL ;
SERAFINO, RP ;
POSS, MA ;
GU, Z ;
RYONO, DE ;
MORELAND, S ;
POWELL, JR .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (01) :179-189
[9]   Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-tranfected Chinese hamster ovary cells [J].
Fierens, F ;
Vanderheyden, PML ;
De Backer, JP ;
Vauquelin, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 367 (2-3) :413-422
[10]   Insurmountable angiotensin AT1 receptor antagonists:: the role of tight antagonist binding [J].
Fierens, FLP ;
Vanderheyden, PML ;
De Backer, JP ;
Vauquelin, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 372 (02) :199-206